Jessica Fye

Stock Analyst at JP Morgan

(4.53)

# 278

Out of 5,115 analysts

215

Total ratings

63.7%

Success rate

15.87%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - Specialty & Generic Medical Devices Drug Manufacturers - General

Stocks Rated by Jessica Fye

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	DNLI Denali Therapeutics	Maintains: Overweight	$24 → $26	$21.74	+19.60%	6	Nov 4, 2025
	STOK Stoke Therapeutics	Maintains: Neutral	$15 → $25	$30.37	-17.68%	5	Nov 3, 2025
	NVCR NovoCure	Maintains: Neutral	$25 → $23	$12.40	+85.48%	5	Oct 27, 2025
	JAZZ Jazz Pharmaceuticals	Maintains: Overweight	$204 → $199	$164.49	+20.98%	5	Oct 27, 2025
	HALO Halozyme Therapeutics	Maintains: Neutral	$63 → $65	$71.71	-9.36%	15	Oct 27, 2025
	MRNA Moderna	Maintains: Underweight	$26 → $25	$44.07	-43.27%	14	Oct 23, 2025
	BNTX BioNTech SE	Maintains: Neutral	$121 → $120	$113.75	+5.49%	14	Oct 23, 2025
	ALNY Alnylam Pharmaceuticals	Maintains: Overweight	$475 → $473	$338.06	+39.92%	9	Oct 13, 2025
	LEGN Legend Biotech	Maintains: Overweight	$78 → $76	$17.50	+334.29%	4	Oct 9, 2025
	INCY Incyte	Maintains: Neutral	$73 → $89	$100.07	-11.06%	9	Oct 9, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$116 → $119	$56.54	+110.47%	5	Oct 9, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$260 → $264	$226.10	+16.76%	16	Oct 9, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$517 → $530	$469.90	+12.79%	10	Oct 8, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$345 → $385	$340.38	+13.11%	4	Oct 8, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Overweight	$49 → $80	$82.67	-3.23%	7	Oct 8, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$53 → $52	$49.94	+4.12%	6	Sep 24, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$53 → $77	$103.22	-25.40%	4	Sep 12, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Neutral	$34 → $35	$33.89	+3.28%	7	Sep 9, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$111 → $135	$156.87	-13.94%	9	Aug 20, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$350 → $330	$469.49	-29.71%	17	Jul 8, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$10 → $13	$6.58	+97.57%	6	May 6, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$54 → $50	$32.55	+53.61%	5	Apr 14, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$30	$36.85	-18.59%	1	Oct 8, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Reinstates: Underweight	n/a	$37.33	-	7	Nov 20, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Reinstates: Underweight	n/a	$11.34	-	2	Nov 20, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Reinstates: Neutral	n/a	$3.39	-	9	Nov 20, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Reinstates: Underweight	n/a	$14.92	-	6	Nov 20, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Downgrades: Underweight	n/a	$0.80	-	2	Aug 20, 2021
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Neutral	$7	$1.16	+503.45%	2	Jan 29, 2021
	XXXX XXXXXXXXXXXXXXXX Upgrade	Downgrades: Underweight	n/a	$8.85	-	3	Feb 28, 2019
	XXXX XXXXXXXXXXXXXXXX Upgrade	Downgrades: Neutral	n/a	$12.90	-	1	Feb 8, 2018

Denali Therapeutics

Nov 4, 2025

Maintains: Overweight

Price Target: $24 → $26

Current: $21.74

Upside: +19.60%

Stoke Therapeutics

Nov 3, 2025

Maintains: Neutral

Price Target: $15 → $25

Current: $30.37

Upside: -17.68%

NovoCure

Oct 27, 2025

Maintains: Neutral

Price Target: $25 → $23

Current: $12.40

Upside: +85.48%

Jazz Pharmaceuticals

Oct 27, 2025

Maintains: Overweight

Price Target: $204 → $199

Current: $164.49

Upside: +20.98%

Halozyme Therapeutics

Oct 27, 2025

Maintains: Neutral

Price Target: $63 → $65

Current: $71.71

Upside: -9.36%

Moderna

Oct 23, 2025

Maintains: Underweight

Price Target: $26 → $25

Current: $44.07

Upside: -43.27%

BioNTech SE

Oct 23, 2025

Maintains: Neutral

Price Target: $121 → $120

Current: $113.75

Upside: +5.49%

Alnylam Pharmaceuticals

Oct 13, 2025

Maintains: Overweight

Price Target: $475 → $473

Current: $338.06

Upside: +39.92%

Legend Biotech

Oct 9, 2025

Maintains: Overweight

Price Target: $78 → $76

Current: $17.50

Upside: +334.29%

Incyte

Oct 9, 2025

Maintains: Neutral

Price Target: $73 → $89

Current: $100.07

Upside: -11.06%

Oct 9, 2025

Maintains: Overweight

Price Target: $116 → $119

Current: $56.54

Upside: +110.47%

Oct 9, 2025

Maintains: Overweight

Price Target: $260 → $264

Current: $226.10

Upside: +16.76%

Oct 8, 2025

Maintains: Overweight

Price Target: $517 → $530

Current: $469.90

Upside: +12.79%

Oct 8, 2025

Maintains: Overweight

Price Target: $345 → $385

Current: $340.38

Upside: +13.11%

Oct 8, 2025

Upgrades: Overweight

Price Target: $49 → $80

Current: $82.67

Upside: -3.23%

Sep 24, 2025

Maintains: Overweight

Price Target: $53 → $52

Current: $49.94

Upside: +4.12%

Sep 12, 2025

Maintains: Overweight

Price Target: $53 → $77

Current: $103.22

Upside: -25.40%

Sep 9, 2025

Maintains: Neutral

Price Target: $34 → $35

Current: $33.89

Upside: +3.28%

Aug 20, 2025

Maintains: Overweight

Price Target: $111 → $135

Current: $156.87

Upside: -13.94%

Jul 8, 2025

Maintains: Overweight

Price Target: $350 → $330

Current: $469.49

Upside: -29.71%

May 6, 2025

Maintains: Overweight

Price Target: $10 → $13

Current: $6.58

Upside: +97.57%

Apr 14, 2025

Maintains: Overweight

Price Target: $54 → $50

Current: $32.55

Upside: +53.61%

Oct 8, 2024

Initiates: Overweight

Price Target: $30

Current: $36.85

Upside: -18.59%

Nov 20, 2023

Reinstates: Underweight

Price Target: n/a

Current: $37.33

Upside: -

Nov 20, 2023

Reinstates: Underweight

Price Target: n/a

Current: $11.34

Upside: -

Nov 20, 2023

Reinstates: Neutral

Price Target: n/a

Current: $3.39

Upside: -

Nov 20, 2023

Reinstates: Underweight

Price Target: n/a

Current: $14.92

Upside: -

Aug 20, 2021

Downgrades: Underweight

Price Target: n/a

Current: $0.80

Upside: -

Jan 29, 2021

Upgrades: Neutral

Price Target: $7

Current: $1.16

Upside: +503.45%

Feb 28, 2019

Downgrades: Underweight

Price Target: n/a

Current: $8.85

Upside: -

Feb 8, 2018

Downgrades: Neutral

Price Target: n/a

Current: $12.90

Upside: -